Company intelligence / Profile preview
Lactocore
Plymouth, Michigan, United Stateslactocore.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Lactocore's lead peptide program (LCGA-17) is advancing toward Phase 1 trials for anxiety disorders after promising preclinical animal data in stress and behavioral models. Another asset, CHM-273, has shown efficacy in animal models of metabolic disease, affecting insulin resistance and inflammation. All pipeline assets are currently preclinical or at discovery/IND-enabling stage; no clinical results in humans have been reported yet.
- Therapeutic areas
- NeurologyMetabolic DisordersPsychiatry
- Modalities
- PeptidesSynthetic peptideSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ingredia (French dairy company, for functional food ingredients and R&D collaboration)Centre for Human Drug Research (Netherlands, for clinical biomarker studies)
Beyond the preview
Go deeper on Lactocore.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactocore.